Tislelizumab

About beigene

BeiGene has rapidly evolved from a research-focused startup into a leading global oncology company with a vertically integrated model spanning R&D, manufacturing, and commercialization. Its strategic pivot to internal R&D yielded the blockbuster-in-waiting BRUKINSA, which has achieved multiple FDA approvals and is competing head-to-head with established BTK inhibitors. The company's strategy leverages its deep roots in China for development efficiency and cost-effective manufacturing, while its substantial infrastructure in the U.S. and Europe supports global commercial ambitions.

Therapeutic Areas